Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

June 08, 2006 09:10 ET

Swiss Medica Continues To Receive International Attention For O24 Fibromyalgia

TORONTO, ONTARIO--(CCNMatthews - June 8, 2006) - Swiss Medica, Inc. (OTCBB:SWME) announced today that international recognition continues to grow for its patented, all natural and clinically tested product O24 Fibromyalgia, with official approval by the Fibromyalgia Support Group Surrey & Sussex in the United Kingdom.

O24 Fibromyalgia is the first clinically-tested product available in national pharmacies to help patients fight the intense, debilitating pain caused by Fibromyalgia.

O24 Fibromyalgia was launched in late 2005 in the United States when the product was awarded the first ever Seal of Approval from the California-based National Fibromyalgia Association (NFA). Upwards of 11 million Americans suffer from this debilitating chronic ailment.

Similar recognition for O24™ Fibromyalgia was received by the FM-CFS (Fibromyalgia and Chronic Fatigue Syndrome) of Canada late last year, the group representing Fibromyalgia patients in Canada.

In early 2005, Swiss Medica conducted research, which involved a double blind clinical trial by Dr. Gordon Ko (Head, Fibromyalgia Clinic) and Dr. David Berbrayer (Head, Dept. Rehabilitation Medicine) at Sunnybrook & Women's Health Sciences Centre (University of Toronto in Ontario, Canada). This clinical trial demonstrated that 88% of the patients using the O24™ Fibromyalgia product reported mild to markedly better improvement on the 7-point Lanier rating scale, versus only 7% who used the placebo. A copy of Dr. Ko's study is available for review at

Swiss Medica also announced today that Raghu Kilambi, Swiss Medica's Co-Founder and CEO, has recently purchased 575,000 Class A common shares of Swiss Medica on the open market and through the exercise of stock options. Mr. Kilambi has purchased, since May 30th, 425,000 shares of Swiss Medica common shares on the open market and has purchased 150,000 shares by exercising stock options. Details of these purchases are included in Form 4's that have been filed with the S.E.C. and accessible via the investor section of

Mr. Kilambi stated "I continue to believe that our shares are undervalued based on the market potential of our products. This insider buying reflects my belief in Swiss Medica's strategy, our products and our team."

About Swiss Medica, Inc.

Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our websites at, and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit, for ordering details and store locators for the nearest retailer.

Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information